Intangible Assets

3 Months Ended

Mar. 31, 2018

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Intangible Assets

INTANGIBLE ASSETS

The following table summarizes the carrying amount of our intangible assets, net (in millions):

	March 31, 2018		December 31, 2017
Finite-lived intangible assets	$	14,053	$	14,350
Indefinite-lived intangible assets	2,750		2,750
Total intangible assets	$	16,803	$	17,100

The following table summarizes our finite-lived intangible assets (in millions):

	March 31, 2018									December 31, 2017
	Gross  Carrying Amount		Accumulated Amortization			Foreign Currency Translation Adjustment		Net Carrying Amount		Gross  Carrying Amount		Accumulated Amortization			Net Carrying Amount
Intangible asset - sofosbuvir	$	10,720	$	(3,030	)	$	—	$	7,690	$	10,720	$	(2,855	)	$	7,865
Intangible asset - axicabtagene ciloleucel (DLBCL)	6,200		(158		)	—		6,042		6,200		(72		)	6,128
Intangible asset - Ranexa	688		(594		)	—		94		688		(566		)	122
Other	546		(323		)	4		227		546		(311		)	235
Total	$	18,154	$	(4,105	)	$	4	$	14,053	$	18,154	$	(3,804	)	$	14,350

Amortization expense related to finite-lived intangible assets, included in Cost of goods sold on our Condensed Consolidated Statements of Income, totaled $301 million for the three months ended March 31, 2018 and $210 million for the three months ended March 31, 2017. As of March 31, 2018, estimated future amortization expense associated with our finite-lived intangible assets is as follows (in millions):

Fiscal Year	Amount
2018 (remaining nine months)	$	902
2019	1,089
2020	1,064
2021	1,064
2022	1,064
Thereafter	8,870
Total	$	14,053